UBE2B Antibody

Basic Research Methodologies

• What is UBE2B and why is it important in cellular research?

  UBE2B (Ubiquitin-conjugating enzyme E2 B, also known as RAD6B) is a 17 kDa E2 ubiquitin-conjugating enzyme that plays a crucial role in the ubiquitination pathway. It accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to substrate proteins through cooperation with E3 ligases . UBE2B is particularly important in post-replication repair of UV-damaged DNA and has been found to interact with RAD18 . Additionally, it mediates beta-catenin polyubiquitination and stabilization, thereby activating the Wnt signaling pathway . Research interest in UBE2B has grown significantly due to its involvement in multiple cellular processes including DNA repair, transcriptional regulation through histone modification, and its emerging role as a potential prognostic biomarker in several cancers .

• What applications can UBE2B antibodies be effectively used for?

  UBE2B antibodies have been validated for multiple research applications with varying dilution requirements:

  Application	Recommended Dilution	Common Antibody Types	Source
  Western Blot (WB)	1:500-1:3000	Polyclonal, Monoclonal
  Immunohistochemistry (IHC)	1:50-1:500	Polyclonal
  Immunofluorescence (IF)	1-2 μg/ml	Monoclonal
  Flow Cytometry	1-2 μg/million cells	Monoclonal
  ELISA	Variable (antibody-dependent)	Polyclonal, Monoclonal

  When designing experiments, researchers should conduct preliminary titration studies to determine optimal antibody concentrations for their specific experimental conditions and sample types .

• How should researchers differentiate between UBE2B and other E2 family members in experimental design?

  Distinguishing between UBE2B and other E2 family members (particularly its close homolog UBE2A) requires careful experimental planning. These approaches are recommended:

  • Select antibodies raised against unique epitopes within UBE2B that do not share sequence homology with other E2 enzymes

  • Validate antibody specificity using positive controls (e.g., recombinant UBE2B protein) and negative controls (e.g., UBE2B knockout cells)

  • Consider using complementary techniques such as mass spectrometry to confirm antibody specificity

  • When performing functional studies, use genetic approaches (siRNA/shRNA) targeting UBE2B-specific sequences to corroborate antibody-based findings

  • If available, use UBE2B knockout or knockdown cells as negative controls in antibody validation experiments

  UBE2A and UBE2B share significant sequence homology but differ in their functions. Both are essential for post-replication repair of UV-damaged DNA and interact with RAD18, but they may have distinct substrate preferences and cellular roles .

Advanced Research Applications

• How can UBE2B antibodies be optimally employed in cancer prognostic research?

  Recent studies have identified UBE2B as a potential prognostic biomarker in several cancer types, including esophageal carcinoma (ESCA) and rectal cancer . When using UBE2B antibodies for cancer prognostic research, researchers should:

  • Employ standardized immunohistochemistry protocols with validated antibody dilutions (typically 1:50-1:500)

  • Compare UBE2B expression between tumor and adjacent normal tissues

  • Correlate expression levels with clinicopathological parameters and patient outcomes

  • Stratify patients based on UBE2B expression levels (high vs. low) when analyzing survival data

  • Consider the tumor microenvironment context, as UBE2B expression correlates with immune cell infiltration patterns in ESCA

  • Validate findings using multiple antibody clones or complementary techniques (RT-qPCR, Western blot)

  In ESCA studies, high UBE2B expression was significantly correlated with poor survival outcomes and was associated with altered immune cell infiltration, including increases in CD8+ T cells and macrophages, but decreases in effector memory T cells and Th17 cells .

• What methodological considerations are important when studying UBE2B's role in DNA damage response?

  When investigating UBE2B's function in DNA repair mechanisms, researchers should:

  • Utilize UBE2B antibodies in combination with antibodies against DNA damage markers (γH2AX, 53BP1, RAD51)

  • Employ immunofluorescence co-localization assays to detect UBE2B recruitment to DNA damage sites

  • Consider chromatin fractionation approaches to separate nuclear soluble and chromatin-bound UBE2B

  • Use DNA damaging agents (UV, ionizing radiation) as experimental stimuli

  • Include time-course experiments to track the dynamic recruitment and dissociation of UBE2B from repair complexes

  Research has shown that inhibition of UBE2B elevates the genotoxicity of ionizing radiation in radioresistant cell lines. Importantly, the recruitment of 53BP1 and Rad51 is remarkably prolonged in cells after pre-treatment with UBE2B inhibitor TZ9, suggesting a defective DNA repair pathway in UBE2B-deficient cells .

• How can UBE2B antibodies facilitate research on its role in histone modification and epigenetic regulation?

  UBE2B plays a critical role in epigenetic regulation through its ability to monoubiquitinate histone H2B at Lysine-120 (H2BK120ub1) in conjunction with the E3 enzyme BRE1 (RNF20/RNF40). This modification serves as a specific tag for epigenetic transcriptional activation . To study this function:

  • Use UBE2B antibodies in chromatin immunoprecipitation (ChIP) assays to identify genomic regions where UBE2B is recruited

  • Perform sequential ChIP (re-ChIP) with UBE2B antibodies followed by antibodies against H2BK120ub1 to establish direct relationship

  • Combine with antibodies against other histone modifications (H3K4me, H3K79me) that are dependent on H2BK120ub1

  • Employ proximity ligation assays to detect UBE2B interactions with histone modifying complexes

  • Validate findings using UBE2B depletion or overexpression approaches followed by global histone modification analysis

  The H2BK120ub1 modification generated through UBE2B activity is a prerequisite for subsequent H3K4 and H3K79 methylation, creating a cascade of epigenetic marks that regulate transcription, telomeric silencing, and elongation by RNA polymerase II .

• What are the optimal approaches for studying UBE2B in targeted protein degradation systems?

  Recent research has demonstrated that UBE2B can be engineered into chimeric degrader molecules (E2 bioPROTACs) capable of inducing targeted protein degradation . When investigating UBE2B in this context:

  • Use antibodies to monitor expression levels and subcellular localization of both UBE2B and target proteins

  • Employ co-immunoprecipitation with UBE2B antibodies to identify interaction partners in degradation complexes

  • Consider pulse-chase experiments with cycloheximide to measure protein degradation kinetics

  • Compare E2B-based degraders with traditional E3-based systems using quantitative proteomics

  • Validate the specificity of degradation through rescue experiments with proteasome inhibitors

  Studies have shown that certain human E2 enzymes, particularly E2B and E2D1, can be fused to target-binding scaffolds to drive the degradation of specific human intracellular proteins such as SHP2 and KRAS . UBE2B has been identified as particularly efficient in degradation platforms within recent proteome-wide proximity-inducing screens.

• How should researchers approach UBE2B antibody validation when studying its correlation with immune infiltration in cancer?

  The correlation between UBE2B expression and immune cell infiltration in tumors requires robust antibody validation:

  • Validate antibody specificity in immunohistochemistry using positive and negative tissue controls

  • Perform parallel analyses with multiple detection methods (IHC, IF, flow cytometry)

  • Consider multiplex immunofluorescence to simultaneously detect UBE2B and immune cell markers

  • Use bioinformatic approaches like Single-Sample Gene Set Enrichment Analysis (ssGSEA) to correlate UBE2B expression with immune cell signatures

  • Validate findings using immune cell depletion or reconstitution models

  Research has shown that high UBE2B expression correlates with increased infiltration of CD8+ T cells, Th1 cells, and macrophages, while effector memory T cells and Th17 cells showed decreased presence in tumors with high UBE2B expression . These findings suggest UBE2B may play a role in modulating the tumor immune microenvironment.

• What controls should be included when validating UBE2B antibodies for research applications?

  Proper antibody validation is critical for obtaining reliable results. For UBE2B antibodies, include:

  Control Type	Description	Purpose
  Positive Control	Recombinant UBE2B protein, cell lines with known UBE2B expression (L02 cells, HEK-293 cells)	Confirms antibody binding to target
  Negative Control	UBE2B knockout/knockdown cells, isotype control antibody	Establishes specificity and background levels
  Peptide Competition	Pre-incubation of antibody with immunogen peptide	Confirms epitope specificity
  Cross-Reactivity Control	Closely related proteins (UBE2A/other E2 enzymes)	Assesses unintended binding
  Loading Control	Housekeeping proteins (β-actin, GAPDH) for Western blot	Normalizes protein loading
  Tissue Controls	Human ovary tumor tissue has been validated for IHC	Establishes tissue-level expression patterns

  For optimal results, researchers should perform antigen retrieval with TE buffer pH 9.0 or alternatively with citrate buffer pH 6.0 when conducting IHC with UBE2B antibodies .

• How can UBE2B antibodies be used to investigate its role in cancer therapeutic resistance?

  UBE2B has been implicated in therapeutic resistance, particularly in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy (CCRT) . To investigate this role:

  • Compare UBE2B expression in pre- and post-treatment tumor samples using validated antibody dilutions

  • Correlate UBE2B expression with tumor regression grade and treatment response

  • Perform in vitro studies with radiation-resistant cell lines, modulating UBE2B expression and monitoring sensitivity changes

  • Use UBE2B antibodies in combination with DNA damage response markers to assess repair efficiency

  • Consider cell cycle analysis in conjunction with UBE2B staining to identify cell cycle-dependent effects

  Clinical data has indicated that UBE2B expression significantly correlates with tumor regression grade. Inhibition of UBE2B elevated the genotoxicity of ionizing radiation to radioresistant cell lines, while UBE2B overexpression reduced cell sensitivity to radiation . These findings suggest that UBE2B could serve as both a predictive biomarker and potential therapeutic target for overcoming radiation resistance.

Technical Considerations

• What are the optimal storage and handling conditions for maintaining UBE2B antibody efficacy?

  To maintain antibody quality and performance over time:

  • Store at -20°C in appropriate buffer conditions (typically PBS with 0.02% sodium azide and 50% glycerol, pH 7.3)

  • Antibodies are generally stable for one year after shipment when properly stored

  • Avoid repeated freeze-thaw cycles; consider aliquoting for long-term storage

  • Some preparations may contain BSA (0.1%) for additional stabilization

  • Before use, allow antibody to equilibrate to room temperature and mix gently

  • Follow manufacturer-specific recommendations, as formulations may vary between suppliers

  • Validate antibody performance periodically, especially with aged stocks

  Proper storage and handling are essential for maintaining specificity and sensitivity in research applications, particularly for quantitative analyses of UBE2B expression in clinical samples.

• What strategies can resolve conflicting results when using different UBE2B antibodies?

  When faced with discrepant results from different UBE2B antibodies:

  • Compare the epitopes recognized by each antibody (N-terminal, C-terminal, or internal regions)

  • Consider antibody format differences (polyclonal vs. monoclonal, different host species)

  • Evaluate possible post-translational modifications that might affect epitope accessibility

  • Confirm results with orthogonal techniques (RT-qPCR, mass spectrometry)

  • Validate with functional assays (siRNA knockdown, CRISPR-Cas9 knockout)

  • Analyze potential splice variants of UBE2B that might be differentially recognized

  • Compare antibody performance across different experimental conditions and sample types

  Different UBE2B antibodies may recognize distinct epitopes or conformational states of the protein, potentially leading to varying results depending on the experimental context and the specific biological question being addressed.